Family Office Real Estate Daily · Family Office Real Estate Research Desk · Preview
Research Desk
A curated index of 20,204 CRE market research reports from the major institutional publishers — filterable by asset class, market and publisher. Editorial Family-Office interpretation layer is rolling out report-by-report.
Showing Family Office Briefings with a Co-GP / Platform angle — each card surfaces how a family office could deploy capital in that market.
22 reports
Page 1 / 1- CBREApr 29, 2026
Philadelphia Life Sciences Figures Q1 2026
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsApr 15, 2026
Philadelphia Q1 2026 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level to share in the promote and access a pipeline of opportunities.
- SavillsJan 14, 2026
Philadelphia Q4 2025 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into this market by backing a sponsor focused on life sciences developments, leveraging co-GP or JV equity structures to align interests and share in the upside.
- SavillsOct 10, 2025
Philadelphia Q3 2025 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level to share in the promote and access a pipeline of projects.
- CBREAug 6, 2025
Philadelphia Life Sciences Figures Report Q2 2025
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsJul 12, 2025
Philadelphia Q2 2025 Life Sciences Market Overview
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level, sharing in the promote and benefiting from a strong pipeline of developments.
- SavillsApr 11, 2025
Philadelphia Q1 2025 Life Sciences Market Overview
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level, sharing in the promote and benefiting from a repeatable pipeline of investment opportunities.
- SavillsFeb 5, 2025
Philadelphia Q4 2024 Life Sciences Market Overview
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level, focusing on established firms with a strong track record in the sector.
- CBREJan 17, 2025
Philadelphia Life Sciences Figures Report Q4 2024
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level, focusing on co-GP or JV equity to share in the promote.
- ColliersDec 11, 2024
2024 Philadelphia Life Sciences Market Report: Opportunity Post Uncertainty
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level, sharing in the promote and aligning interests.
- SavillsNov 6, 2024
Philadelphia Q3 2024 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- CBREOct 11, 2024
Philadelphia Life Sciences Figures Report Q3 2024
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsAug 7, 2024
Philadelphia Q2 2024 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level, particularly in the context of the new biotech developments and revitalization projects.
- CBREJul 24, 2024
Philadelphia Life Sciences Figures Report Q2 2024
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsMay 10, 2024
Philadelphia Q1 2024 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator at the GP level to share in the promote and access a pipeline of investment opportunities.
- CBREApr 12, 2024
Philadelphia Life Sciences Figures Report Q1 2024
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and access a repeatable pipeline.
- CBREMar 6, 2024
Philadelphia Life Sciences Figures Report Q4 2023
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsJan 31, 2024
Philadelphia Q4 2023 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and access a repeatable deal flow.
- CBRENov 8, 2023
Philadelphia Life Sciences Figures Report Q3 2023
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- SavillsNov 3, 2023
Philadelphia 2023 Q3 Life Sciences Market Report
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor/operator involved in the construction of new lab spaces to share in the promote and benefit from the growing tenant demand.
- CBREJul 14, 2023
Philadelphia Life Sciences Figures Report Q2 2023
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
- CBREApr 25, 2023
Philadelphia Life Sciences Figures Report Q1 2023
Co-GP / Platform:A family office could deploy into the Philadelphia life sciences market by backing a sponsor or operator at the GP level to share in the promote and benefit from their expertise.
Research Hubs
Dedicated pages for every major publisher and market — each with aggregated KPI medians, asset-class breakdowns and the latest reports, read through a family-office lens.